Abstract
Abstract
Objective
Describe the demographic profile of US participants in Amgen clinical trials over a 10-year period and variations across therapeutic areas, indications, and geographies.
Methods
Cross-sectional retrospective study including participants enrolled (2005–2020) in phase 1–3 trials completed between January 1, 2012 and June 30, 2021.
Results
Among 31,619 participants enrolled across 258 trials, one-fifth represented racial minority populations (Asian, 3%; Black or African American, 17%; American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, multiracial, each < 1%); fewer than one-fifth (16%) represented an ethnic minority population (Hispanic or Latino). Compared with census data, representation of racial and ethnic groups varied across US states. Across most therapeutic areas (bone, cardiovascular, hematology/oncology, inflammation, metabolic disorders, neuroscience) except nephrology, participants were predominantly White (72–81%). A similar proportion of males and females were enrolled between 2005 and 2016; male representation was disproportionately higher than female between 2016 and 2020. Across most medical indications, the majority of participants were 18–65 years of age.
Conclusions and Relevance
While the clinical research community is striving to achieve diversity and proportional representation across clinical trials, certain populations remain underrepresented. Our data provide a baseline assessment of the diversity and representation of US participants in Amgen-sponsored clinical trials and add to a growing body of evidence on the importance of diversity in clinical research. These data provide a foundation for strategies aimed at supporting more equitable and representative research, and a baseline from which to assess the impact of future strategies to advance health equity.
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health,Health Policy,Sociology and Political Science,Anthropology,Health (social science)
Reference58 articles.
1. Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials: guidance for industry (draft guidance). U.S. Department of Health and Human Services, Food and Drug Administration, Oncology Center of Excellence (OCE), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH), Office of Minority Health and Health Equity (OMHHE). Accessed September, 2022.https://www.fda.gov/media/157635/download.
2. Ramamoorthy A, Knepper TC, Merenda C, et al. Demographic composition of select oncologic new molecular entities approved by the FDA between 2008 and 2017. Clin Pharmacol Ther. 2018;104(5):940–8. https://doi.org/10.1002/cpt.1180.
3. Sharma A, Palaniappan L. Improving diversity in medical research. Nat Rev Dis Primers. 2021;7(1):74. https://doi.org/10.1038/s41572-021-00316-8.
4. Knepper TC, McLeod HL. When will clinical trials finally reflect diversity? Accessed November 16, 2022.https://www.nature.com/articles/d41586-018-05049-5.
5. National Academies of Sciences, Engineering, and Medicine; Policy and Global Affairs; Committee on Women in Science, Engineering, and Medicine; Committee on Improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research. Improving representation in clinical trials and research: building research equity for women and underrepresented groups. In: Bibbins-Domingo K, Helman A, editors. Washington (DC): National Academies Press (US); 2022.